Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. - Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C (Journal of neurology, 2012)